Stepan Company
NYSE:SCLChemicals - Specialty
+$0.46 today
- Market cap
- $1.50B
- Beta
- 0.97
- P/E (TTM)
- -87.3
- EPS (TTM)
- -$0.62
- Dividend yield
- 2.89%
Volume 0.13M
Average 0.15M
SCL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Stepan CompanyNYSE: SCL
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $46.19M (cash outflow) rose 14.5% year over year, ahead of the +8.9% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 1.0% of revenue in FY2025, up 0.6 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +14.5% holds above the trailing-twelve-month pace of +8.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 23.72M USD
- Year-over-year change
- +162.5%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.72M | +162.5% |
| FY2024 | 2024-12-31 | 9.04M | -71.8% |
| FY2023 | 2023-12-31 | 32.01M | +159.1% |
| FY2022 | 2022-12-31 | (54.17M) | +48.0% |
| FY2021 | 2021-12-31 | (104.23M) | — |
Accounts Receivables vs competitors
How SCL compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +8.9% is the 6th highest of 10, against a peer median of +23.7%.
- Accounts receivables amounts to 0.8% of revenue for SCL, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | R$640.8M BRL | -208.2% | -59.0% | 1.0% | |
| LTM Mar 2026 | $32.21M USD | -2084.4% | — | 3.9% | |
| LTM Mar 2026 | $18.8M USD | +23.7% | — | 1.0% | |
| LTM Mar 2026 | $17.88M USD | +8.9% | — | 0.8% | |
| LTM Mar 2026 | $13.94M USD | -91.5% | — | 1.0% | |
| LTM Mar 2026 | $11.2M USD | -156.9% | — | 1.7% | |
| LTM Mar 2026 | $10.61M USD | +211.1% | +31.3% | 0.5% | |
| LTM Apr 2026 | $10.18M USD | +548.2% | -9.9% | 2.1% | |
| LTM Apr 2026 | $8.56M USD | +191.2% | +118.0% | 1.3% | |
| LTM Mar 2026 | $1.01M USD | +68.0% | — | 3.8% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding SCL) | — | +23.7% | +10.7% | 1.2% | |
Competitors are the stored peer set for SCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 137.9M | 147.15M | 40.2M | 50.37M | 46.9M |
| Depreciation & Amortization | 90.88M | 94.65M | 105.34M | 112.2M | 126.04M |
| Deferred Income Tax | (33.61M) | (27.45M) | 18.3M | (10.29M) | (1.4M) |
| Stock-Based Compensation | 11.72M | 13.85M | 5.74M | 5.35M | 2.16M |
| Change in Working Capital | (141.51M) | (68.96M) | (1.93M) | 2.79M | (22.04M) |
| Accounts Receivables | (104.23M) | (54.17M) | 32.01M | 9.04M | 23.72M |
| Inventory | (79.26M) | (99.39M) | 144.85M | (37.18M) | 500K |
| Accounts Payables | 44.41M | 54.17M | (158.92M) | 33.97M | (32.71M) |
| Other Working Capital | (2.44M) | 30.43M | (19.86M) | (3.04M) | (13.55M) |
| Other Non-Cash Items | 6.76M | 1.53M | 7.22M | 1.64M | (3.78M) |
| Operating Cash Flow | 72.14M | 160.76M | 174.88M | 162.05M | 147.88M |
| Capital Expenditures | (194.48M) | (301.55M) | (260.34M) | (122.78M) | (122.51M) |
| Acquisitions (Net) | (184.47M) | (9.69M) | 0 | 0 | 26.59M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 2.13M | 3.16M | 1.67M | 5.83M | 6.88M |
| Investing Cash Flow | (376.83M) | (308.09M) | (258.67M) | (116.95M) | (89.05M) |
| Debt Repayment | 165M | 223.69M | 66.86M | (28.69M) | 1.24M |
| Common Stock Issued | 0 | 0 | 2.8M | 1.11M | 104K |
| Common Stock Repurchased | (16.97M) | (24.95M) | 0 | 0 | 0 |
| Dividends Paid | (28.08M) | (30.57M) | (32.87M) | (33.95M) | (35.03M) |
| Other Financing Activities | (2.62M) | (1.96M) | (3.5M) | (3M) | (1.76M) |
| Financing Cash Flow | 117.33M | 166.21M | 33.28M | (64.52M) | (35.44M) |
| Effect of Forex Changes | (3.39M) | (4.32M) | 6.58M | (10.75M) | 9.63M |
| Net Change in Cash | (190.75M) | 14.56M | (43.93M) | (30.16M) | 33.02M |
| Free Cash Flow | (122.35M) | (140.79M) | (85.46M) | 39.28M | 25.37M |
Stepan Company
NYSE:SCL
Intrinsic Alpha fair value
Locked
Current Price
$66.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.